Aspartate aminotransferase (AST) is widely distributed, principally in liver, heart, skeletal muscle, kidney and red blood cells. Increased concentrations are found in diseases involving these tissues. Specifically hepatobiliary diseases including cirrhosis, metastatic cancer and viral hepatitis increase serum AST levels. Following myocardial infarction, AST is elevated and reaches a peak 2 days after onset. AST levels may be decreased in patients undergoing dialysis or with vitamin B6 deficiency.
No special patient preparation required.
Haemolysis interferes with measurement of AST activity.
Adult male/female reference range: 11-34 U/L (Abbott Alinity)
NEQAS for Clinical Chemistry Scheme
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962